Clinical Scorecard: Office-Based Therapies Gain Ground in Glaucoma Care
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Selective laser trabeculoplasty (SLT) and sustained drug delivery systems to lower intraocular pressure (IOP). |
| Target Population | Patients with glaucoma requiring IOP management. |
| Care Setting | Office-based therapies. |
Key Highlights
- SLT and sustained drug delivery can reduce reliance on IOP-lowering drops.
- Office-based procedures allow for earlier intervention in glaucoma management.
- Chronic use of IOP-lowering drops may compromise surgical outcomes.
- Durysta and iDose TR are FDA-approved sustained-release drug delivery systems.
- SLT remains underutilized as a first-line therapy despite proven efficacy.
Guideline-Based Recommendations
Diagnosis
- Assess IOP and visual field loss to diagnose glaucoma.
Management
- Consider SLT and sustained drug delivery as first-line therapies.
Monitoring & Follow-up
- Regularly evaluate IOP and patient adherence to treatment.
Risks
- Long-term drop therapy may lead to ocular surface disease and scarring.
Patient & Prescribing Data
Patients with glaucoma on multiple classes of medications.
Office-based therapies can enhance compliance and quality of life.
Clinical Best Practices
- Utilize SLT as a first-line treatment option.
- Incorporate sustained drug delivery systems to improve patient outcomes.
- Educate patients on the benefits of early intervention and compliance.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.